Severity score system for progressive myelopathy: development and validation of a new clinical scale

Progressive myelopathies can be secondary to inborn errors of metabolism (IEM) such as mucopolysaccharidosis, mucolipidosis, and adrenomyeloneuropathy. The available scale, Japanese Orthopaedic Association (JOA) score, was validated only for degenerative vertebral diseases. Our objective is to propose and validate a new scale addressing progressive myelopathies and to present validating data for JOA in these diseases. A new scale, Severity Score System for Progressive Myelopathy (SSPROM), covering motor disability, sphincter dysfunction, spasticity, and sensory losses. Inter- and intra-rater reliabilities were measured. External validation was tested by applying JOA, the Expanded Disability Status Scale (EDSS), the Barthel index, and the Osame Motor Disability Score. Thirty-eight patients, 17 with adrenomyeloneuropathy, 3 with mucopolysaccharidosis I, 3 with mucopolysaccharidosis IV, 2 with mucopolysaccharidosis VI, 2 with mucolipidosis, and 11 with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy participated in the study. The mean ± SD SSPROM and JOA scores were 74.6 ± 11.4 and 12.4 ± 2.3, respectively. Construct validity for SSPROM (JOA: r = 0.84, P < 0.0001; EDSS: r = -0.83, P < 0.0001; Barthel: r = 0.56, P < 0.002; Osame: r = -0.94, P < 0.0001) and reliability (intra-rater: r = 0.83, P < 0.0001; inter-rater: r = 0.94, P < 0.0001) were demonstrated. The metric properties of JOA were similar to those found in SSPROM. Several clinimetric requirements were met for both SSPROM and JOA scales. Since SSPROM has a wider range, it should be useful for follow-up studies on IEM myelopathies.

Saved in:
Bibliographic Details
Main Authors: Castilhos,R.M., Blank,D., Netto,C.B.O., Souza,C.F.M., Fernandes,L.N.T., Schwartz,I.V.D., Giugliani,R., Jardim,L.B.
Format: Digital revista
Language:English
Published: Associação Brasileira de Divulgação Científica 2012
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000700001
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0100-879X2012000700001
record_format ojs
spelling oai:scielo:S0100-879X20120007000012012-06-22Severity score system for progressive myelopathy: development and validation of a new clinical scaleCastilhos,R.M.Blank,D.Netto,C.B.O.Souza,C.F.M.Fernandes,L.N.T.Schwartz,I.V.D.Giugliani,R.Jardim,L.B. Japanese Orthopaedic Association Severity Score System for Progressive Myelopathy Mucopolysaccharidosis Mucolipidosis Adrenomyeloneuropathy Progressive myelopathies Progressive myelopathies can be secondary to inborn errors of metabolism (IEM) such as mucopolysaccharidosis, mucolipidosis, and adrenomyeloneuropathy. The available scale, Japanese Orthopaedic Association (JOA) score, was validated only for degenerative vertebral diseases. Our objective is to propose and validate a new scale addressing progressive myelopathies and to present validating data for JOA in these diseases. A new scale, Severity Score System for Progressive Myelopathy (SSPROM), covering motor disability, sphincter dysfunction, spasticity, and sensory losses. Inter- and intra-rater reliabilities were measured. External validation was tested by applying JOA, the Expanded Disability Status Scale (EDSS), the Barthel index, and the Osame Motor Disability Score. Thirty-eight patients, 17 with adrenomyeloneuropathy, 3 with mucopolysaccharidosis I, 3 with mucopolysaccharidosis IV, 2 with mucopolysaccharidosis VI, 2 with mucolipidosis, and 11 with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy participated in the study. The mean ± SD SSPROM and JOA scores were 74.6 ± 11.4 and 12.4 ± 2.3, respectively. Construct validity for SSPROM (JOA: r = 0.84, P < 0.0001; EDSS: r = -0.83, P < 0.0001; Barthel: r = 0.56, P < 0.002; Osame: r = -0.94, P < 0.0001) and reliability (intra-rater: r = 0.83, P < 0.0001; inter-rater: r = 0.94, P < 0.0001) were demonstrated. The metric properties of JOA were similar to those found in SSPROM. Several clinimetric requirements were met for both SSPROM and JOA scales. Since SSPROM has a wider range, it should be useful for follow-up studies on IEM myelopathies.info:eu-repo/semantics/openAccessAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research v.45 n.7 20122012-07-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000700001en10.1590/S0100-879X2012007500072
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Castilhos,R.M.
Blank,D.
Netto,C.B.O.
Souza,C.F.M.
Fernandes,L.N.T.
Schwartz,I.V.D.
Giugliani,R.
Jardim,L.B.
spellingShingle Castilhos,R.M.
Blank,D.
Netto,C.B.O.
Souza,C.F.M.
Fernandes,L.N.T.
Schwartz,I.V.D.
Giugliani,R.
Jardim,L.B.
Severity score system for progressive myelopathy: development and validation of a new clinical scale
author_facet Castilhos,R.M.
Blank,D.
Netto,C.B.O.
Souza,C.F.M.
Fernandes,L.N.T.
Schwartz,I.V.D.
Giugliani,R.
Jardim,L.B.
author_sort Castilhos,R.M.
title Severity score system for progressive myelopathy: development and validation of a new clinical scale
title_short Severity score system for progressive myelopathy: development and validation of a new clinical scale
title_full Severity score system for progressive myelopathy: development and validation of a new clinical scale
title_fullStr Severity score system for progressive myelopathy: development and validation of a new clinical scale
title_full_unstemmed Severity score system for progressive myelopathy: development and validation of a new clinical scale
title_sort severity score system for progressive myelopathy: development and validation of a new clinical scale
description Progressive myelopathies can be secondary to inborn errors of metabolism (IEM) such as mucopolysaccharidosis, mucolipidosis, and adrenomyeloneuropathy. The available scale, Japanese Orthopaedic Association (JOA) score, was validated only for degenerative vertebral diseases. Our objective is to propose and validate a new scale addressing progressive myelopathies and to present validating data for JOA in these diseases. A new scale, Severity Score System for Progressive Myelopathy (SSPROM), covering motor disability, sphincter dysfunction, spasticity, and sensory losses. Inter- and intra-rater reliabilities were measured. External validation was tested by applying JOA, the Expanded Disability Status Scale (EDSS), the Barthel index, and the Osame Motor Disability Score. Thirty-eight patients, 17 with adrenomyeloneuropathy, 3 with mucopolysaccharidosis I, 3 with mucopolysaccharidosis IV, 2 with mucopolysaccharidosis VI, 2 with mucolipidosis, and 11 with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy participated in the study. The mean ± SD SSPROM and JOA scores were 74.6 ± 11.4 and 12.4 ± 2.3, respectively. Construct validity for SSPROM (JOA: r = 0.84, P < 0.0001; EDSS: r = -0.83, P < 0.0001; Barthel: r = 0.56, P < 0.002; Osame: r = -0.94, P < 0.0001) and reliability (intra-rater: r = 0.83, P < 0.0001; inter-rater: r = 0.94, P < 0.0001) were demonstrated. The metric properties of JOA were similar to those found in SSPROM. Several clinimetric requirements were met for both SSPROM and JOA scales. Since SSPROM has a wider range, it should be useful for follow-up studies on IEM myelopathies.
publisher Associação Brasileira de Divulgação Científica
publishDate 2012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2012000700001
work_keys_str_mv AT castilhosrm severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT blankd severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT nettocbo severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT souzacfm severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT fernandeslnt severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT schwartzivd severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT giuglianir severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
AT jardimlb severityscoresystemforprogressivemyelopathydevelopmentandvalidationofanewclinicalscale
_version_ 1756391401933766656